TEVA PHARMACEUTICAL INDUSTRIES LTD - Ordinary Shares, par value NIS 0.01 per share (TEVA)

Q: What does CUSIP 881624209 represent in this 13F holders report?

CUSIP 881624209 is the security identifier for TEVA - TEVA PHARMACEUTICAL INDUSTRIES LTD - Ordinary Shares, par value NIS 0.01 per share used to aggregate holder disclosures.

Q: How many institutions held TEVA - TEVA PHARMACEUTICAL INDUSTRIES LTD - Ordinary Shares, par value NIS 0.01 per share in Q1 2017?

683 institutional investors reported TEVA - TEVA PHARMACEUTICAL INDUSTRIES LTD - Ordinary Shares, par value NIS 0.01 per share for Q1 2017. Use the holders table for investor-level position and value details.

CUSIP: 881624209

Q1 2017 13F Holders as of 31 Mar 2017

Type / Class: Equity / Ordinary Shares, par value NIS 0.01 per share
Shares outstanding: 1,148,777,709
Total 13F shares: 577,358,917
Share change: +5,833,627
Total reported value: $18,532,232,773
Put/Call ratio: 203%
Price per share: $32.09
Number of holders: 683
Value change: +$137,211,832
Number of buys: 314
Number of sells: 361

Quarterly Holders Quick Answers

What is CUSIP 881624209?
CUSIP 881624209 identifies TEVA - TEVA PHARMACEUTICAL INDUSTRIES LTD - Ordinary Shares, par value NIS 0.01 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q2 2017
Previous quarter: Q4 2016

Recent filing periods for CUSIP 881624209:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of TEVA - TEVA PHARMACEUTICAL INDUSTRIES LTD - Ordinary Shares, par value NIS 0.01 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
FMR LLC	13F	Company	5.5%	63,005,615	$2,283,953,000	—	31 Dec 2016	13F
FRANKLIN RESOURCES INC	13F	Company	4.9%	56,635,303	$2,052,926,000	—	31 Dec 2016	13F
Capital Research Global Investors	13F	Company	3.9%	44,396,747	$1,609,382,000	—	31 Dec 2016	13F
BARROW HANLEY MEWHINNEY & STRAUSS LLC	13F	Company	2.8%	32,455,432	$1,176,510,000	—	31 Dec 2016	13F
Bank of New York Mellon Corp	13F	Company	1.7%	19,715,313	$714,680,000	—	31 Dec 2016	13F
HIGHFIELDS CAPITAL MANAGEMENT LP	13F	Company	1.5%	16,867,447	$611,445,000	—	31 Dec 2016	13F
PAULSON & CO. INC.	13F	Company	1.4%	15,925,800	$577,310,000	—	31 Dec 2016	13F
Invesco Ltd.	13F	Company	1.3%	14,866,203	$538,899,000	—	31 Dec 2016	13F
NORGES BANK	13F	Company	1.2%	13,680,233	$495,909,000	—	31 Dec 2016	13F
NORDEA INVESTMENT MANAGEMENT AB	13F	Company	1.2%	13,260,411	$480,690,000	—	31 Dec 2016	13F
BlackRock Institutional Trust Company, N.A.	13F	Company	1.1%	12,724,714	$461,271,000	—	31 Dec 2016	13F
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	1%	11,873,418	$430,411,000	—	31 Dec 2016	13F
WADDELL & REED FINANCIAL INC	13F	Company	0.93%	10,630,453	$385,354,000	—	31 Dec 2016	13F
LAZARD ASSET MANAGEMENT LLC	13F	Company	0.89%	10,206,724	$369,993,000	—	31 Dec 2016	13F
JPMORGAN CHASE & CO	13F	Company	0.78%	8,928,162	$323,646,000	—	31 Dec 2016	13F
JANUS HENDERSON GROUP PLC	13F	Company	0.71%	8,106,352	$293,977,000	—	31 Dec 2016	13F
ALLIANCEBERNSTEIN L.P.	13F	Company	0.7%	8,029,857	$291,082,000	—	31 Dec 2016	13F
BlackRock Fund Advisors	13F	Company	0.63%	7,252,632	$262,908,000	—	31 Dec 2016	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	0.63%	7,248,829	$262,770,000	—	31 Dec 2016	13F
MORGAN STANLEY	13F	Company	0.63%	7,201,609	$261,058,000	—	31 Dec 2016	13F
NORTHERN TRUST CORP	13F	Company	0.56%	6,406,616	$232,240,000	—	31 Dec 2016	13F
Appaloosa LP	13F	Company	0.44%	5,053,000	$183,171,000	—	31 Dec 2016	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.42%	4,780,228	$173,284,000	—	31 Dec 2016	13F
Camber Capital Management LP	13F	Company	0.41%	4,724,450	$171,261,000	—	31 Dec 2016	13F
SCHRODER INVESTMENT MANAGEMENT GROUP	13F	Company	0.41%	4,713,132	$170,851,000	—	31 Dec 2016	13F
Migdal Insurance & Financial Holdings Ltd.	13F	Company	0.4%	4,564,560	$165,461,000	—	31 Dec 2016	13F
JANUS HENDERSON INVESTORS US LLC	13F	Company	0.37%	4,272,331	$154,902,000	—	31 Dec 2016	13F
THOMPSON SIEGEL & WALMSLEY LLC	13F	Company	0.37%	4,260,852	$154,455,000	—	31 Dec 2016	13F
PUTNAM INVESTMENTS LLC	13F	Company	0.34%	3,957,817	$143,470,000	—	31 Dec 2016	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.34%	3,920,945	$142,134,000	—	31 Dec 2016	13F
STATE STREET CORP	13F	Company	0.34%	3,908,973	$141,705,000	—	31 Dec 2016	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.33%	3,778,985	$136,988,000	—	31 Dec 2016	13F
TWO SIGMA ADVISERS, LP	13F	Company	0.33%	3,766,599	$136,539,000	—	31 Dec 2016	13F
Swiss National Bank	13F	Company	0.32%	3,630,251	$131,597,000	—	31 Dec 2016	13F
BROWN ADVISORY INC	13F	Company	0.28%	3,206,518	$116,236,000	—	31 Dec 2016	13F
FIR TREE CAPITAL MANAGEMENT LP	13F	Company	0.28%	3,177,812	$115,196,000	—	31 Dec 2016	13F
BlackRock Group LTD	13F	Company	0.27%	3,075,439	$111,485,000	—	31 Dec 2016	13F
PICTET ASSET MANAGEMENT LTD	13F	Company	0.27%	3,044,591	$110,366,000	—	31 Dec 2016	13F
ROYAL BANK OF CANADA	13F	Company	0.25%	2,854,342	$103,471,000	—	31 Dec 2016	13F
BlackRock Investment Management, LLC	13F	Company	0.24%	2,761,360	$100,099,000	—	31 Dec 2016	13F
Russell Investments Group, Ltd.	13F	Company	0.23%	2,697,428	$97,312,000	—	31 Dec 2016	13F
Sumitomo Mitsui Trust Group, Inc.	13F	Company	0.23%	2,668,233	$96,723,000	—	31 Dec 2016	13F
Neuberger Berman Group LLC	13F	Company	0.22%	2,554,328	$92,594,000	—	31 Dec 2016	13F
NN Investment Partners Holdings N.V.	13F	Company	0.22%	2,522,200	$91,430,000	—	31 Dec 2016	13F
D. E. Shaw & Co., Inc.	13F	Company	0.21%	2,392,049	$86,712,000	—	31 Dec 2016	13F
TD ASSET MANAGEMENT INC	13F	Company	0.19%	2,168,246	$78,599,000	—	31 Dec 2016	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.19%	2,165,863	$78,513,000	—	31 Dec 2016	13F
EARNEST PARTNERS LLC	13F	Company	0.19%	2,162,741	$78,399,000	—	31 Dec 2016	13F
Clearbridge Investments, LLC	13F	Company	0.19%	2,153,899	$78,079,000	—	31 Dec 2016	13F
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	13F	Company	0.17%	2,004,760	$72,672,000	—	31 Dec 2016	13F

Institutional Holders of TEVA PHARMACEUTICAL INDUSTRIES LTD - Ordinary Shares, par value NIS 0.01 per share (TEVA) as of Q1 2017

As of 31 Mar 2017, TEVA PHARMACEUTICAL INDUSTRIES LTD - Ordinary Shares, par value NIS 0.01 per share (TEVA) was held by 683 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 577,358,917 shares. The largest 10 holders included Capital Research Global Investors, FRANKLIN RESOURCES INC, FMR LLC, BARROW HANLEY MEWHINNEY & STRAUSS LLC, BlackRock Inc., Bank of New York Mellon Corp, HIGHFIELDS CAPITAL MANAGEMENT LP, WELLINGTON MANAGEMENT GROUP LLP, Northern Cross, LLC, and Invesco Ltd.. This page lists 684 institutional shareholders reporting positions in this security for the Q1 2017 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q1 2017 vs Q4 2016 Across Filers

Q4 2016 holders

728

Q1 2017 holders

683

Holder diff

-45

Investor	Q4 2016 Shares	Q1 2017 Shares	Share Diff	Share Chg %	Q4 2016 Value $	Q1 2017 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.